{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:58:37Z","timestamp":1785549517476,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40618-019-01105-7","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T15:06:19Z","timestamp":1566831979000},"page":"219-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"L.","family":"Scappaticcio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Virili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bellastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Campenn\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Giovanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Trimboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"key":"1105_CR1","doi-asserted-by":"publisher","first-page":"a032029","DOI":"10.1101\/cshperspect.a032029","volume":"8","author":"S Katsavos","year":"2018","unstructured":"Katsavos S, Coles A (2018) Alemtuzumab as treatment for multiple sclerosis. Cold Spring Harb Perspect Med 8:a032029. \nhttps:\/\/doi.org\/10.1101\/cshperspect.a032029","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1105_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1586\/ern.12.5","volume":"12","author":"L Costelloe","year":"2012","unstructured":"Costelloe L, Jones J, Coles A (2012) Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 12:335\u2013341. \nhttps:\/\/doi.org\/10.1586\/ern.12.5","journal-title":"Expert Rev Neurother"},{"key":"1105_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","volume":"99","author":"GH Daniels","year":"2014","unstructured":"Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80\u201389. \nhttps:\/\/doi.org\/10.1210\/jc.2013-2201","journal-title":"J Clin Endocrinol Metab"},{"issue":"103","key":"1105_CR4","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1210\/jc.2018-00359","volume":"1","author":"N Pariani","year":"2018","unstructured":"Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, Lyons G, Jones J, Chatterjee K, Dayan C, Robertson N, Coles A, Moran C (2018) Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab 1(103):3010\u20133018. \nhttps:\/\/doi.org\/10.1210\/jc.2018-00359","journal-title":"J Clin Endocrinol Metab"},{"key":"1105_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/cen.12427","volume":"80","author":"AP Weetman","year":"2014","unstructured":"Weetman AP (2014) Graves\u2019 disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently? Clin Endocrinol 80:629\u2013632. \nhttps:\/\/doi.org\/10.1111\/cen.12427","journal-title":"Clin Endocrinol"},{"issue":"8","key":"1105_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fendo.2017.00254","volume":"28","author":"M Rotondi","year":"2017","unstructured":"Rotondi M, Molteni M, Leporati P, Capelli V, Marin\u00f2 M, Chiovato L (2017) Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol 28(8):254. \nhttps:\/\/doi.org\/10.3389\/fendo.2017.00254","journal-title":"Front Endocrinol"},{"issue":"1","key":"1105_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.14310\/horm.2002.1501","volume":"14","author":"E Tsourdi","year":"2015","unstructured":"Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC (2015) Graves\u2019 disease after treatment with alemtuzumab for multiple sclerosis. Hormones 14(1):148\u2013153. \nhttps:\/\/doi.org\/10.14310\/horm.2002.1501","journal-title":"Hormones"},{"key":"1105_CR8","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma G (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. \nhttps:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"issue":"12","key":"1105_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","volume":"41","author":"E Masiello","year":"2018","unstructured":"Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, Tanda ML, Chiovato L, Wiersinga WM, Bartalena L (2018) Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41(12):1425\u20131432. \nhttps:\/\/doi.org\/10.1007\/s40618-018-0918-9","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"1105_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016) 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343\u20131421","journal-title":"Thyroid"},{"key":"1105_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"1105_CR12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1089\/thy.2018.0232","volume":"28","author":"I Muller","year":"2018","unstructured":"Muller I, Willis M, Healy S, Nasser T, Loveless S, Butterworth S, Zhang L, Draman MS, Taylor PN, Robertson N, Dayan CM, Ludgate ME (2018) Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years. Thyroid 28:1682\u20131693. \nhttps:\/\/doi.org\/10.1089\/thy.2018.0232","journal-title":"Thyroid"},{"issue":"2","key":"1105_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","volume":"86","author":"O Tuohy","year":"2015","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Fahey MT, Jones J, Compston DA, Coles A (2015) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatr 86(2):208\u2013215. \nhttps:\/\/doi.org\/10.1136\/jnnp-2014-307721","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"77","key":"1105_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","volume":"9","author":"M Cossburn","year":"2011","unstructured":"Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 9(77):573\u2013579. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e318228bec5","journal-title":"Neurology"},{"issue":"11","key":"1105_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89(11):1107\u20131116. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000004313","journal-title":"Neurology"},{"key":"1105_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"AJ Coles","year":"2017","unstructured":"Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hoga RJ, Panzara MA, Arnold DL (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89:1117\u20131126. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000004354","journal-title":"Neurology"},{"key":"1105_CR17","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"394","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 394:1691\u20131695","journal-title":"Lancet"},{"issue":"2","key":"1105_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1468-1331.2011.03507.x","volume":"19","author":"EJ Fox","year":"2012","unstructured":"Fox EJ, Sullivan HC, Gazda SK, Mayer L, O\u2019Donnell L, Melia K, Lake SL (2012) A single-arm, open-label study of alemtuzumab in treatment refractory patients with multiple sclerosis. Eur J Neurol 19(2):307\u2013311. \nhttps:\/\/doi.org\/10.1111\/j.1468-1331.2011.03507.x","journal-title":"Eur J Neurol"},{"key":"1105_CR19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Behcet\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology 42:1539\u20131544","journal-title":"Rheumatology"},{"key":"1105_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1210\/jc.2018-01652","volume":"104","author":"A Dunn","year":"2019","unstructured":"Dunn A, Lam A, Hidalgo L, Shapiro AMJ, Senior PA (2019) Autoimmune thyroid disease in islet transplant recipients discontinuing immunosuppression late after lymphodepletion. J Clin Endocrinol Metab 104:1141\u20131147. \nhttps:\/\/doi.org\/10.1210\/jc.2018-01652","journal-title":"J Clin Endocrinol Metab"},{"key":"1105_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","volume":"6","author":"AD Kirk","year":"2006","unstructured":"Kirk AD, Hale DA, Swanson SJ, Mannon RB (2006) Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 6:1084\u20131085","journal-title":"Am J Transplant"},{"issue":"11","key":"1105_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1089\/thy.2013.0241","volume":"23","author":"F Torino","year":"2013","unstructured":"Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM (2013) Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23(11):1345\u20131366. \nhttps:\/\/doi.org\/10.1089\/thy.2013.0241","journal-title":"Thyroid"},{"issue":"5","key":"1105_CR23","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/cen.12060","volume":"78","author":"HF Nystrom","year":"2013","unstructured":"Nystrom HF, Jansson S, Berg G (2013) Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003\u20132005. Clin Endocrinol 78(5):768\u2013776. \nhttps:\/\/doi.org\/10.1111\/cen.12060","journal-title":"Clin Endocrinol"},{"issue":"Pt 6","key":"1105_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/brain\/123.6.1102","volume":"123","author":"SA Broadley","year":"2000","unstructured":"Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA (2000) Autoimmune disease in first-degree relatives of patients with multiple sclerosis: a UK survey. Brain 123(Pt 6):1102\u20131111","journal-title":"Brain"},{"issue":"1","key":"1105_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/thy.2012.0374","volume":"23","author":"SM McLachlan","year":"2013","unstructured":"McLachlan SM, Rapoport B (2013) Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 23(1):14\u201324. \nhttps:\/\/doi.org\/10.1089\/thy.2012.0374","journal-title":"Thyroid"},{"key":"1105_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326. \nhttps:\/\/doi.org\/10.1159\/000443828","journal-title":"Eur Thyroid J"},{"issue":"3","key":"1105_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1210\/jc.2013-2409","volume":"99","author":"A Garmendia Madariaga","year":"2014","unstructured":"Garmendia Madariaga A, Santos Palacios S, Guill\u00e9n-Grima F, Galofr\u00e9 JC (2014) The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99(3):923\u2013931. \nhttps:\/\/doi.org\/10.1210\/jc.2013-2409","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1105_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/1352458514564490","volume":"21","author":"RA Marrie","year":"2015","unstructured":"Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M (2015) A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler 21(3):282\u2013293. \nhttps:\/\/doi.org\/10.1177\/1352458514564490","journal-title":"Mult Scler"},{"issue":"348","key":"1105_CR29","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1056\/NEJMra021194","volume":"26","author":"EN Pearce","year":"2003","unstructured":"Pearce EN, Farwell AP, Braverman LE (2003) Thyroiditis. N Engl J Med 26(348):2646\u20132655","journal-title":"N Engl J Med"},{"issue":"23","key":"1105_CR30","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2015.16535","volume":"314","author":"HB Burch","year":"2015","unstructured":"Burch HB, Cooper DS (2015) Management of graves disease: a review. JAMA 314(23):2544\u20132554. \nhttps:\/\/doi.org\/10.1001\/jama.2015.16535","journal-title":"JAMA"},{"issue":"10","key":"1105_CR31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves\u2019 disease: frequently asked questions and answers (if any). J Endocrinol Invest 39(10):1105\u20131114. \nhttps:\/\/doi.org\/10.1007\/s40618-016-0505-x","journal-title":"J Endocrinol Invest"},{"key":"1105_CR32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI109601","volume":"64","author":"LC Wood","year":"1979","unstructured":"Wood LC, Ingbar SH (1979) Hypothyroidism as a late sequela in patient with Graves\u2019 disease treated with antithyroid agents. J Clin Invest 64:1429\u20131436","journal-title":"J Clin Invest"},{"key":"1105_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1089\/thy.2005.15.687","volume":"15","author":"KA Woeber","year":"2005","unstructured":"Woeber KA (2005) Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15:687\u2013691","journal-title":"Thyroid"},{"issue":"1","key":"1105_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2265.2012.04345.x","volume":"77","author":"G Das","year":"2012","unstructured":"Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE (2012) Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol 77(1):146\u2013151. \nhttps:\/\/doi.org\/10.1111\/j.1365-2265.2012.04345.x","journal-title":"Clin Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01105-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T23:31:08Z","timestamp":1598311868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01105-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01105-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,26]]},"assertion":[{"value":"24 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Since this is a meta-analysis, informed consent is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}